Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Posts falsely claim Malaysian minister to relocate public hospital for temple - 2Novo Nordisk gears up for December Ozempic launch in India, sources say
- 3Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis
- 4Central African Republic's president sworn in for a third term after disputed election
- 5The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- Make your choice for the music application with the most amicable connection point!
- Teen drug use remains low, but survey finds small rise in heroin and cocaine use
- Reality TV star Spencer Pratt, who lost his home in Palisades Fire, is running for mayor of Los Angeles
- Ice Spice's 'Big Guy' SpongeBob song is stuck in everyone's heads again — and TikTok is fueling it
- Support Your Investment funds with These Individual accounting Thoughts
- CPA Canada appoints eight directors as new governance model takes effect
- 13 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- 6 Solid Moving Administrations for a Calm Movement
- Gulf countries roll out more autonomous taxis
